Jupiter Neurosciences sells $3.6M in stock to Yorkville under equity line

Jupiter Neurosciences, Inc. disclosed in an 8-K dated July 28, 2026 that it sold additional shares of common stock to YA II PN, Ltd., known as Yorkville, under a standing financing arrangement.

The company had entered into a Standby Equity Purchase Agreement with Yorkville, a Cayman Islands exempt limited partnership, on October 24, 2025, giving Jupiter the right but not the obligation to sell up to $20,000,000 of common stock over time, subject to conditions in the agreement.¹ The arrangement was first described in an 8-K filed October 27, 2025, and later amended by an 8-K/A filed November 20, 2025.¹

Between May 14, 2026 and July 24, 2026, under Advance Notices delivered pursuant to the SEPA, the company issued and sold 11,470,000 shares of common stock to Yorkville for aggregate gross proceeds of approximately $3.6 million.¹ The per-share price for each advance was set at 97% of the lowest daily volume-weighted average price of the stock on Nasdaq during a three-trading-day pricing period beginning on the date each Advance Notice was delivered.¹

The shares were issued under an exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, based on Yorkville's representations that it is an accredited investor acquiring the shares for investment rather than distribution.¹

Following these sales, the company reported 56,520,143 shares of common stock issued and outstanding as of July 28, 2026.¹ The filing was signed by Christer Rosén, listed as Chief Executive Officer.